My research activities are concentrated on cancer screening and early diagnosis. There is potential for considerable saving of lives from cancer if it were diagnosed at an earlier stage.
Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet (2017) 389:1299-1311. PMID: 28236467
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol (2016) 17(1):109-14. PMID: 26655422
Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single arm FH01 study. Lancet Oncol (2010) 11: 1127-34. PMID: 21093374
Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during three decades. Radiol (2011) 260: 658-63. PMID: 21712474
2019-2023- NIHR, Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, £5M
Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme Ghimire B, Maroni R, Vulkan D et al. Lung Cancer (2019) 134(7) 66-71
Reply to The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Duffy SW, Smith RA, Tabár L et al. Cancer (2019) 125(2) 2130-2131
Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial. Ruparel M, Quaife SL, Ghimire B et al. Ann Am Thorac Soc (2019) 16(2) 744-751
Risk stratification in breast screening: A word of caution. Duffy SW J Med Screen (2019) 26(2) 57-58
Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer. Aarts AMWM, Duffy SW, Geurts SME et al. Breast (2019) 45(2) 70-74
Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. Marcus MW, Duffy SW, Devaraj A et al. Thorax (2019) (2)
Correction: Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study. Singh D, Miettinen J, Duffy S et al. Br J Cancer (2019) 120(2) 773-774
Rapid review of factors associated with flexible sigmoidoscopy screening use. Kerrison RS, von Wagner C, Green T et al. Prev Med (2019) 120(2) 8-18
The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Tabár L, Dean PB, Chen TH-H et al. Cancer (2019) 125(2) 515-523
“They say it’s more aggressive in black women”: Biosociality, breast cancer and becoming a population ‘at risk’ BROWN TW, Greenhough B, DYCK I et al. Transactions of the Institute of British Geographers (2019) (1)For additional publications, please click here
Oleg Blyuss, Amanda Dibden, Roberta Maroni, Daniel Vulkan
Senior Data Manager
I am a statistician by training, educated at the University of Edinburgh and Imperial College, London. I have worked in the UK, Singapore, France, Sweden and Russia.
For the last three decades, my research has been mainly in cancer epidemiology, prevention and screening. I worked on the pioneering Swedish Two-County Trial of breast cancer screening, on which the UK's national breast screening programme was based.
Since then I have taken a major role in a number of other trials of cancer screening, in breast, colorectal and lung cancer. These include the UK Trial of Flexible Sigmoidoscopy whose results changed national policy within weeks of publication, and the FH01 study of annual mammography in young women at enhanced familial risk of breast cancer, which contributed to the NICE guidelines on breast cancer risk management.
I am currently Director of the Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, funded by the Department of Health.
It is a collaboration between researchers from seven institutions (Queen Mary University of London, UCL, King's College London, London School of Hygiene and Tropical Medicine, Hull York Medical School, Durham University and Peninsula Medical School). The aim of the unit is to carry out research to inform policy to promote earlier diagnosis of cancer, symptomatically or by screening, and as a consequence bring down mortality from cancer.
In our strand of the Unit in Queen Mary University of London, our team concentrates on research aimed at evaluating cancer screening programmes, and devising innovations to these which will improve their effect on death from cancer, enhance their acceptability to the public and minimise side effects of screening, such as false positive rates.